Default: Current Problems in Cancer

ISSN: 0147-0272

Journal Home

Journal Guideline

Current Problems in Cancer Q2 Unclaimed

Elsevier Inc. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Current Problems in Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 47. It has an SJR impact factor of 0,759 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,759.

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Current Problems in Cancer

0,759

SJR Impact factor

47

H Index

50

Total Docs (Last Year)

226

Total Docs (3 years)

2582

Total Refs

551

Total Cites (3 years)

216

Citable Docs (3 years)

2.48

Cites/Doc (2 years)

51.64

Ref/Doc

Comments

No comments ... Be the first to comment!



Best articles by citations

Clinicopathologic significance of LAIR-1 expression in hepatocellular carcinoma

View more

Preface

View more

Current multimodality management of medulloblastoma

View more

Molecular Alternations in Uveal Melanoma

View more

Foreword

View more

Foreword

View more

Foreword

View more

Foreword

View more

Foreword

View more

Foreword

View more

Chemoprevention in prostate cancer

View more

Chemoprevention of breast cancer

View more
SHOW MORE ARTICLES

Hereditary Melanoma

View more

Issues, both ethical and practical, in the development and conduct of chemoprevention trials

View more

Foreword

View more

Foreword

View more

Esophageal cancer: A systematic review

View more

Foreword

View more

Foreword

View more

Foreword

View more

Echocardiographic evolution of left ventricular function in childhood leukemia survivors

View more

Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations

View more

Foreword

View more

Foreword

View more

FAQS